NCT06816524

The Effects of Iron Treatment on Malaria and Measles Vaccine Response in Kenyan Infants With Iron Deficiency

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 324 (estimated)
• Sponsor: Nicole Stoffel · Academic / Other
• Sex: All
• Age: 6 Months – 6 Months
• Healthy volunteers: Not accepted

Summary

Malaria and iron deficiency cause a significant burden of disease in Africa. Iron deficiency (ID) might affect immune responses to vaccination. In this double-blind randomized controlled trial, we aim to assess: (1) whether ID impairs R21/Matrix-M and measles (MR) vaccine response, (2) whether iron treatment at time of vaccination improves vaccine response.

Conditions

• Iron Deficiencies

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Iron syrup	Iron syrup administered daily from 6 to 10 months of age.
DIETARY_SUPPLEMENT	Multivitamin syrup	Multivitamin syrup administered daily from 6 to 10 months of age.
BIOLOGICAL	R21-Matrix/M Vaccine (malaria vaccine)	R21-Matrix/M vaccine administered in 3 doses at 7, 8 and 9 months of age.
BIOLOGICAL	Measles-Rubella vaccine	Measles-Rubella vaccine administered at 9 months of age.

Timeline

• Start date: 2026-01-05
• Primary completion: 2027-12-31
• Completion: 2028-04-30
• First posted: 2025-02-10
• Last updated: 2025-12-26